Related Experiment Videos
[Non-steroid therapy for sarcoidosis].
Mitsuru Konishi1, Ken-ichirou Yoneda, Ken Takahashi
1Second Department of Internal Medicine, Nara Medical University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 18, 2002
Summary
Sarcoidosis treatment is not well-defined, with corticosteroids commonly used but not always effective. Methotrexate and azathioprine are preferred cytotoxic agents for managing this systemic granulomatous disease.
Area of Science:
- Immunology
- Pulmonology
- Rheumatology
Context:
- Sarcoidosis is a complex systemic granulomatous disease with unknown epidemiology.
- Current therapeutic strategies for sarcoidosis are not definitively established.
- Systemic therapy is indicated for specific severe manifestations like cardiac, neurologic, and ocular involvement, hypercalcemia, and progressive disease.
Purpose:
- To review the current understanding of sarcoidosis treatment options.
- To highlight the role of corticosteroids and their limitations.
- To discuss alternative systemic agents used in managing sarcoidosis.
Summary:
- Corticosteroids are a common first-line systemic therapy for sarcoidosis.
- Some patients require alternative treatments due to lack of response or adverse effects from corticosteroids.
- Cytotoxic agents (methotrexate, azathioprine, cyclophosphamide, chlorambucil, cyclosporine A) and antimalarials (chloroquine, hydroxychloroquine) are used, with methotrexate and azathioprine favored for safety and efficacy.
Impact:
- Provides a concise overview of sarcoidosis management.
- Informs clinical decision-making for difficult-to-treat sarcoidosis cases.
- Highlights the need for further research into optimal treatment protocols for sarcoidosis.